Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma

M. Dreyling; P. L. Zinzani; K. Bouabdallah; D. Bron; D. Cunningham; K. Linton; C. Thieblemont; E. Van den Neste; U. Vitolo; J. Grunert; M. Giurescu; S. Mappa; B. H. Childs; F. Morschhauser

Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma

M. Dreyling, P. L. Zinzani, K. Bouabdallah, D. Bron, D. Cunningham, K. Linton, C. Thieblemont, E. Van den Neste, U. Vitolo, J. Grunert, M. Giurescu, S. Mappa, B. H. Childs, F. Morschhauser

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	Undefined
Journal	European Journal of Cancer
Volume	124
Issue number	21
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Dreyling, M., Zinzani, P. L., Bouabdallah, K., Bron, D., Cunningham, D., Linton, K., Thieblemont, C., Van den Neste, E., Vitolo, U., Grunert, J., Giurescu, M., Mappa, S., Childs, B. H., & Morschhauser, F. (2014). Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. European Journal of Cancer, 124(21).

@article{2b03eceacd41432fbfd2735914372990,

title = "Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma",

author = "M. Dreyling and Zinzani, {P. L.} and K. Bouabdallah and D. Bron and D. Cunningham and K. Linton and C. Thieblemont and {Van den Neste}, E. and U. Vitolo and J. Grunert and M. Giurescu and S. Mappa and Childs, {B. H.} and F. Morschhauser",

year = "2014",

language = "Undefined",

volume = "124",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier BV",

number = "21",

}

Dreyling, M, Zinzani, PL, Bouabdallah, K, Bron, D, Cunningham, D, Linton, K, Thieblemont, C, Van den Neste, E, Vitolo, U, Grunert, J, Giurescu, M, Mappa, S, Childs, BH & Morschhauser, F 2014, 'Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma', European Journal of Cancer, vol. 124, no. 21.

TY - JOUR

T1 - Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma

AU - Dreyling, M.

AU - Zinzani, P. L.

AU - Bouabdallah, K.

AU - Bron, D.

AU - Cunningham, D.

AU - Linton, K.

AU - Thieblemont, C.

AU - Van den Neste, E.

AU - Vitolo, U.

AU - Grunert, J.

AU - Giurescu, M.

AU - Mappa, S.

AU - Childs, B. H.

AU - Morschhauser, F.

PY - 2014

Y1 - 2014

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000347755700500&KeyUID=WOS:000347755700500

M3 - Meeting Abstract

SN - 0959-8049

VL - 124

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 21

ER -

Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma

UN SDGs

Other files and links

Cite this